Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details)

v3.23.2
Net Income (Loss) per Share - Schedule of Potentially Dilutive Securities Excluded From Computation of Diluted Net Loss Per Share (Details) - shares
 3 Months Ended 6 Months Ended
Jul. 02, 2023
Jul. 03, 2022
Jul. 02, 2023
Jul. 03, 2022
Stock options outstanding        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities (in shares) 4,425,014 5,359,658 4,425,014 5,359,658
Restricted stock units and performance restricted stock units outstanding        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities (in shares) 13,898,172 5,902,643 13,898,172 5,902,643
Assumed conversion of Convertible Senior Notes        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities (in shares) 8,988,804 0 4,494,402 0
Private Placement Warrants outstanding        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities (in shares) 6,000,000 6,000,000 6,000,000 6,000,000
Employee stock purchase plan estimated shares        
Subsidiary Sale Of Stock [Line Items]        
Anti-dilutive securities (in shares) 562,399 380,847 562,399 380,847